Figure 3

![Figure 3: Visual analog scale scores for abdominal pain and GI discomfort assessment across study visits in IBS patients receiving Bacillus coagulans MTCC 5856 versus placebo. Statistically significant differences (p < 0.01) emerged between groups by visits 3 and 4, with the probiotic group reporting lower pain and reduced GI discomfort.]()

> Source: Muhammed Majeed et al. "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predo." *Nutrition journal*, 2016. PMID: [26922379](https://pubmed.ncbi.nlm.nih.gov/26922379/)

<figure>
  <img src="" alt="Visual analog scale scores for abdominal pain and GI discomfort assessment across study visits in IBS patients receiving Bacillus coagulans MTCC 5856 versus placebo. Statistically significant differences (p < 0.01) emerged between groups by visits 3 and 4, with the probiotic group reporting lower pain and reduced GI discomfort." />
  <figcaption>Figure 3. Visual analog scale scores for abdominal pain and GI discomfort assessment across study visits in IBS patients receiving Bacillus coagulans MTCC 5856 versus placebo. Statistically significant differences (p < 0.01) emerged between groups by visits 3 and 4, with the probiotic group reporting lower pain and reduced GI discomfort.<br>  Source: Muhammed Majeed et al. "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predo." <em>Nutrition journal</em>, 2016. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26922379/">26922379</a></figcaption>
</figure>